Tag: Alector Therapeutics novel Alzheimer’s strategy
Title: Analysis of Alector Therapeutics’ Alzheimer’s Treatment Failure in Phase 2 Study
Alector Therapeutics announced that their Phase 2 trial for a potential Alzheimer's antibody, known as AL002, was unsuccessful. This setback is disappointing as the drug was considered a promising approach to treating the neurodegenerative...